News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,127 Results
Type
Article (14587)
Company Profile (106)
Press Release (260426)
Multimedia
Podcasts (71)
Webinars (13)
Section
Business (88724)
Career Advice (492)
Deals (15459)
Drug Delivery (74)
Drug Development (36985)
Employer Resources (55)
FDA (6422)
Job Trends (6308)
News (151502)
Policy (14173)
Tag
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (448)
Accelerated approval (15)
Adcomms (9)
Allergies (67)
Alliances (23412)
ALS (57)
Alzheimer's disease (486)
Antibody-drug conjugate (ADC) (105)
Approvals (6610)
Artificial intelligence (207)
Autoimmune disease (40)
Automation (12)
Bankruptcy (150)
Best Places to Work (4407)
BIOSECURE Act (10)
Biosimilars (120)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (172)
Cancer (1346)
Cardiovascular disease (152)
Career advice (436)
Career pathing (15)
CAR-T (52)
CDC (8)
Cell therapy (163)
Cervical cancer (9)
Clinical research (32224)
Collaboration (737)
Compensation (325)
Complete response letters (33)
COVID-19 (789)
CRISPR (43)
C-suite (441)
Cystic fibrosis (58)
Data (1833)
Denatured (18)
Depression (47)
Diabetes (126)
Diagnostics (1386)
Digital health (8)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (115)
Drug pricing (116)
Drug shortages (12)
Duchenne muscular dystrophy (83)
Earnings (33627)
Editorial (23)
Employer branding (6)
Employer resources (50)
Events (39193)
Executive appointments (534)
FDA (7522)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (436)
Gene editing (71)
Generative AI (19)
Gene therapy (173)
GLP-1 (442)
Government (1420)
Grass and pollen (4)
Guidances (164)
Healthcare (3622)
HIV (11)
Huntington's disease (10)
IgA nephropathy (37)
Immunology and inflammation (76)
Immuno-oncology (14)
Indications (53)
Infectious disease (854)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (113)
Interviews (63)
IPO (5944)
IRA (33)
Job creations (2071)
Job search strategy (388)
JPM (31)
Kidney cancer (9)
Labor market (32)
Layoffs (218)
Leadership (9)
Legal (3456)
Liver cancer (22)
Longevity (8)
Lung cancer (186)
Lymphoma (126)
Machine learning (13)
Management (18)
Manufacturing (420)
MASH (67)
Medical device (1303)
Medtech (1310)
Mergers & acquisitions (9936)
Metabolic disorders (435)
Multiple sclerosis (46)
NASH (14)
Neurodegenerative disease (86)
Neuropsychiatric disorders (39)
Neuroscience (909)
Neurotech (1)
NextGen: Class of 2026 (1601)
Non-profit (611)
Now hiring (45)
Obesity (228)
Opinion (145)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (51)
Parkinson's disease (81)
Partnered (12)
Patents (221)
Patient recruitment (119)
Peanut (12)
People (29910)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase 1 (8375)
Phase 2 (13601)
Phase 3 (12294)
Pipeline (1924)
Policy (138)
Postmarket research (1404)
Preclinical (3372)
Press Release (25)
Prostate cancer (84)
Psychedelics (16)
Radiopharmaceuticals (137)
Rare diseases (359)
Real estate (2666)
Recruiting (20)
Regulatory (10998)
Reports (15)
Research institute (579)
Resumes & cover letters (60)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (71)
Series A (83)
Series B (50)
Service/supplier (2)
Sickle cell disease (46)
Special edition (11)
Spinal muscular atrophy (84)
Sponsored (9)
Startups (1652)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (75)
The Weekly (51)
Vaccines (243)
Venture capital (34)
Weight loss (141)
Women's health (28)
Worklife (4)
Date
Last 7 days (178)
Last 30 days (711)
Last 365 days (10493)
2026 (964)
2025 (10804)
2024 (12654)
2023 (14420)
2022 (19708)
2021 (20224)
2020 (19124)
2019 (14969)
2018 (11766)
2017 (13959)
2016 (13165)
2015 (15529)
2014 (12446)
2013 (10609)
2012 (11440)
2011 (11948)
2010 (10909)
Location
Africa (320)
Alabama (21)
Alaska (1)
Arizona (77)
Arkansas (3)
Asia (20980)
Australia (2691)
California (3206)
Canada (1482)
China (561)
Colorado (145)
Connecticut (132)
Delaware (123)
Europe (41055)
Florida (602)
Georgia (65)
Hawaii (1)
Idaho (10)
Illinois (358)
India (44)
Indiana (242)
Iowa (2)
Japan (249)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (424)
Massachusetts (2624)
Michigan (46)
Minnesota (166)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (9)
New Jersey (1407)
New Mexico (8)
New York (911)
North Carolina (621)
North Dakota (2)
Northern California (1459)
Ohio (82)
Oklahoma (5)
Oregon (18)
Pennsylvania (718)
Puerto Rico (12)
Rhode Island (17)
South America (510)
South Carolina (11)
Southern California (1391)
Tennessee (53)
Texas (455)
United States (12759)
Utah (61)
Virginia (161)
Washington D.C. (44)
Washington State (224)
West Virginia (1)
Wisconsin (37)
Wyoming (1)
275,127 Results for "takeda pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IN PARTNERSHIP WITH TAKEDA
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research
One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
January 5, 2026
·
5 min read
·
BioSpace Insights
Immunology and inflammation
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data
With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
December 19, 2025
·
2 min read
·
Tristan Manalac
Cell therapy
How Takeda Built Its Cell Therapy Portfolio, Only To Walk Away
Takeda wanted to create something new in the cell therapy world by combining the technology with T cell engagers. A series of acquisitions in 2021 started the process.
October 8, 2025
·
2 min read
·
Annalee Armstrong
Artificial intelligence
Takeda Makes $1B+ AI Bet With Nabla to Build Out Early Pipeline
Nabla and Takeda first joined hands in 2022, to push “the boundaries of next-generation biologics discovery,” according to the startup’s CEO Surge Biswas.
October 14, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets
For $1.2 billion upfront and up to $10.2 billion in milestones, Takeda will gain access to a bispecific antibody fusion protein targeting both the PD-1 and IL-2 pathways, among other assets.
October 22, 2025
·
2 min read
·
Tristan Manalac
Cell therapy
Takeda Exits Cell Therapy Amid Strategic Pivot, Dealing Blow to Once Promising Modality
Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 employees will be let go as part of the move.
October 2, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial
Presenting at the World Sleep Congress 2025, the Dublin-based company’s Phase II study bested Takeda drug in both efficacy and safety.
September 8, 2025
·
2 min read
·
Dan Samorodnitsky
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.
July 14, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
FDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy
The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the protein the therapy replaces.
November 21, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
December 18, 2025
·
15 min read
1 of 27,513
Next
